Invitation to Year End 2012 Conference Call of MorphoSys AG on 5 March 2013

Invitation to Year End 2012 Conference Call of MorphoSys AG on 5 March 2013

ID: 233454

(Thomson Reuters ONE) -
MorphoSys AG /
Invitation to Year End 2012 Conference Call of MorphoSys AG on 5 March 2013
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its Annual
Financial Results 2012 on 5 March 2013 at 7:00 a.m. CET.



The Management team of MorphoSys AG will host a conference call and webcast to
present MorphoSys's Annual Financial Results 2012 and provide an outlook for
2013.



Date:                           Tuesday, 5 March 2013

Time:                         02:00 p.m. CET (01:00 p.m. GMT, 08:00 a.m. EST)



Dial-in numbers (listen only):

Germany:                  +49 89 2444 32975

United Kingdom:      +44 20 3003 2666

USA:                          +1 202 204 1514



Participants of the call will be:

Dr. Simon Moroney, Chief Executive Officer

Jens Holstein, Chief Financial Officer

Dr. Arndt Schottelius, Chief Development Officer

Dr. Marlies Sproll, Chief Scientific Officer




We request that you please dial in up to 10 minutes before the call to ensure a
prompt start and a secure line.

The presentation slides and webcast link will be available at the Company's
website at www.morphosys.com/conference-calls

A slide-synchronized audio replay of the conference will also be available at
the corporate website following the live event.


About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic




antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.

HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®),
Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of
MorphoSys AG.

Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.


This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.


For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors(at)morphosys.com

Media Release (PDF):
http://hugin.info/130295/R/1680818/549451.pdf



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1680818]




Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Norwegian Competition Authority considers to temporarily prohibiting the implementation of the cooperation agreement between ICA and Norgesgruppen KONE wins order for Copenhagen Metro extension
Bereitgestellt von Benutzer: hugin
Datum: 26.02.2013 - 14:00 Uhr
Sprache: Deutsch
News-ID 233454
Anzahl Zeichen: 4658

contact information:
Town:

Martinsried / München



Kategorie:

Business News



Diese Pressemitteilung wurde bisher 207 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Invitation to Year End 2012 Conference Call of MorphoSys AG on 5 March 2013"
steht unter der journalistisch-redaktionellen Verantwortung von

MorphoSys AG (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von MorphoSys AG



 

Werbung



Sponsoren

foodir.org The food directory für Deutschland
News zu Snacks finden Sie auf Snackeo.
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z